Enrico Martin, MD
Cardiovascular Disease · West Des Moines, IANPI 1942229562
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $82,663 of the $112,654 with a category attached, or 73.4%. 22 manufacturers reported payments, led by Boehringer Ingelheim at 51.1% of the total. Among cardiovascular disease clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $420.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$58K
- Lilly USA, LLC$19K
- AstraZeneca$18K
- Heartflow, Inc.$5K
- Siemens Medical Solutions USA, Inc.$4K
- Novo Nordisk$4K
- plus $5K from 16 others
Across 58 payments — averaging $5648.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cleerly, Inc.$156K
- Amgen$99K
- Novartis$48K
- GE HealthCare$19K
- Ionis Pharmaceuticals, Inc.$6K
What the payments were for
- Consulting fees$10,0799%
- Speaking & faculty fees$82,66373%
- Travel & lodging$10,3709%
- Food & beverage$8,5158%
- Education$1,0291%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 74 | $57,581 |
| Lilly USA, LLC | 22 | $18,621 |
| AstraZeneca | 33 | $18,244 |
| Heartflow, Inc. | 28 | $5,486 |
| Siemens Medical Solutions USA, Inc. | 32 | $4,162 |
| Novo Nordisk | 34 | $3,595 |
| GE HealthCare | 5 | $1,730 |
| Bayer | 7 | $1,540 |
| Astellas Pharma US Inc | 6 | $549 |
| E.r. Squibb & Sons, L.L.C. | 9 | $239 |
| Pfizer | 2 | $211 |
| Novartis | 3 | $139 |
| Madrigal Pharmaceuticals | 1 | $125 |
| Ionis Pharmaceuticals, Inc. | 1 | $92 |
| Canon Medical Systems USA, Inc. | 1 | $68 |
| Alnylam Pharmaceuticals Inc. | 1 | $65 |
| Amgen | 2 | $62 |
| Merck | 2 | $59 |
| Bridgebio Pharma, Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$74,774
- FARXIGA$17,784
- FFRct$4,677
- Ozempic$2,871
- MAGNETOM Sola$1,648
- NAEOTOM Alpha$1,346
- SOMATOM Force$1,346
- Kerendia$1,341
- VYNDAQEL$211
- CAMZYOS$125
- RESMETIROM$125
- LEQVIO$113
How this compares
$112,654 in reported general payments places this provider in the 95th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 308 | $280,613 |
| JardianceEmpagliflozin | 170 | $185,180 |
| FarxigaDapagliflozin Propanediol | 103 | $118,418 |
| Repatha SureclickEvolocumab | 157 | $111,451 |
| XareltoRivaroxaban | 74 | $75,412 |
| OzempicSemaglutide | 61 | $62,604 |
| VascepaIcosapent Ethyl | 78 | $54,224 |
| EntrestoSacubitril/Valsartan | 35 | $37,811 |
| Praluent PenAlirocumab | 31 | $18,683 |
| NexletolBempedoic Acid | 17 | $14,572 |
| MultaqDronedarone Hcl | 11 | $10,204 |
| Rosuvastatin Calcium | 623 | $8,193 |
| Ezetimibe | 298 | $7,742 |
| Icosapent Ethyl | 32 | $7,311 |
| Metoprolol Succinate | 324 | $3,986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $211 | $280,613308 claims |
| Boehringer IngelheimJardiance | $57,581 | $185,180170 claims |
| AstraZenecaFarxiga | $18,244 | $118,418103 claims |
| Johnson & JohnsonXarelto | $12 | $75,41274 claims |
| Novo NordiskOzempic | $3,595 | $62,60461 claims |
| NovartisEntresto | $139 | $37,81135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in West Des Moines
- Troy HounshellWest Des Moines$164K
- Suzanne FeigofskyWest Des Moines$59K
- Robert PaulWest Des Moines$9K
- Lucas GrobenWest Des Moines$6K
- Krishna Theja ReddyWest Des Moines$5K
- Randolph RoughWest Des Moines$3K
- Paul WesleyWest Des Moines$2K
- Brian OlshanskyIowa City$219K
- Gursukhman Deep SidhuDavenport$60K
- Tyler RasmussenCedar Rapids$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.